Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clevudine vs Adefovir in Chronic Hepatitis B
NCT01192854Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of clevudine in Chronic Hepatitis B (CHB) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Value of log10 hepatitis B virus (HBV) DNA decreases from baseline at 48 weeks and Histological response at 48 weeks. Started Feb 2010; status: completed.
02
Drugs
clevudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01192854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01192854.